Efipladib, formerly known as PLA902, is a phospholipase inhibitor potentially for the treatment of osteoarthritis and rheumatoid arthritis. In studies, Efipladib was shown to decrease nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid. References: Nickerson-Nutter CL, Goodwin D, Shen MW, Damphousse C, Duan W, Samad TA, McKew JC, Lee KL, Zaleska MM, Mollova N, Clark JD. The cPLA2α inhibitor efipladib decreases nociceptive responses without affecting PGE2 levels in the cerebral spinal fluid. Neuropharmacology. 2011 Mar;60(4):633-41. doi: 10.1016/j.neuropharm.2010.11.025. PubMed PMID: 21146550.

纯度：≥98%

CAS：381683-94-9